Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Mabs|July 26, 2013
Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignanciesSarwish Rafiq, Anthony Siadak, Jonathan P Butchar, et al.
Leukemia Research|March 26, 2015
Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemiaMark C Lanasa, Leslie Andritsos, Jennifer R Brown, et al.
Blood|September 6, 2008
Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cellsRosa Lapalombella, Bo Yu, Georgia Triantafillou, et al.
Blood|June 29, 2012
ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridolEmilia Mahoney, David M Lucas, Sneha V Gupta, et al.
Blood|December 8, 2009
Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathwayRosa Lapalombella, Leslie Andritsos, Qing Liu, et al.
Leukemia & Lymphoma|March 9, 2017
A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomasDouglas W Sborov, Alessandro Canella, Erinn M Hade, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 5, 2019
BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin LymphomaSara Singer, Robert Dean, Qiuhong Zhao, et al.
Bone Marrow Transplantation|February 6, 2019
BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomasSara Singer, Nidhi Sharma, Robert Dean, et al.
Plos One|October 17, 2013
Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to diseaseErin Hertlein, Kyle A Beckwith, Gerard Lozanski, et al.
Cancer Discovery|August 11, 2018
The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter TransformationSean D Reiff, Rose Mantel, Lisa L Smith, et al.
Pageof 4